Chinese drugmaker BeiGene has opened the first phase of a $320 million facility where it intends to manufacture targeted cancer drugs.
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
The Zantac recall is quickly turning into a landslide as CVS pulled Zantac and its generics as did countries from Korea to Bangladesh.
Chi-Med's surufatinib, aiming to challenge Pfizer and Novartis, hits its goal in phase 3 neuroendocrine tumor trial in China.
Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.
Some Takeda over-the-counter and prescription drugs in emerging markets and Western Europe could find new homes soon.
Altogether, seven foreign pharmas won bids in the expanded government drug purchase scheme versus only two in the original "4+7" pilot.
Biocon has scooped up a 60,000-square-foot R&D site in India from Pfizer to advance its biosimilar ambitions.
Keytruda-Lenvima combo wins simultaneous OKs. Eisai and Biogen ditch second BACE drug. Sanofi is leaving Bangladesh. Henlius raises $410 million.